NCT07111520View on ClinicalTrials.gov

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

September 22, 2025

Primary Completion Date

January 31, 2029

Study Completion Date

January 31, 2030

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

BNT326

intravenous (IV) infusion

DRUG

BNT327

IV infusion

DRUG

Pembrolizumab

IV infusion

DRUG

SoC

IV infusion. Combination chemotherapy (pemetrexed, paclitaxel, or carboplatin). Chemotherapy will be selected according to the indication.

Trial Locations (2)

2025

RECRUITING

Institute of Oncology, ARENSIA Exploratory Medicine, Chisinau

22031

RECRUITING

NEXT Virginia, Fairfax

Sponsors

Lead Sponsor

BioNTech SE
All Listed Sponsors
collaborator

MediLink Therapeutics (Suzhou) Co., Ltd.

INDUSTRY

lead

BioNTech SE

INDUSTRY

NCT07111520 - A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter